Clinical Characteristics of Patients with Probable Coronavirus Disease 2019-associated Pulmonary Aspergillosis at a Tertiary Care Hospital in the Republic of Korea: A Case Series
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a life-threatening invasive fungal infection in critically ill patients with COVID-19. However, only a few studies have reported CAPA in the Republic of Korea. Objective: To describe clinical characteristics of CAPA in patients at a tertiary care hospital in the Republic of Korea. Methods: This retrospective, observational consecutive case series study was conducted by reviewing the electronic medical records of patients who developed CAPA at Seoul National University Hospital from January 1, 2020, to August 31, 2021. CAPA was defined by European Confederation of Medical Mycology/International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria. Patient demographics, comorbidities, corticosteroid use, clinical presentation, treatment, and outcomes were investigated. Results: Eleven patients were diagnosed with probable CAPA according to the ECMM/ISHAM criteria. One patient had classical host factor for invasive pulmonary aspergillosis before admission. All patients received corticosteroid therapy before CAPA diagnosis. The mean total corticosteroid administered before CAPA diagnosis was 220 mg of dexamethasone equivalent dose (range, 80~572 mg), and the mean duration of steroid therapy was 15 days (range, 4~34 days). The median time from intensive care unit admission to CAPA diagnosis was 12 days (range, 5~36 days). All individuals showed aggravation on chest X-rays. Ten patients were diagnosed with positive serum galactomannan (GM), and one was diagnosed with positive GM in a bronchoalveolar lavage specimen. Of the 11 patients, 8 received voriconazole-based antifungal therapy for a median of 30.5 days. Only two patients survived after antifungal treatment. Conclusion: These cases illustrate CAPA complicated in critically ill COVID-19 patients. The challenges in diagnosis and poor outcomes of CAPA emphasize the clinical suspicion and needs for further investigation.
Abstract
Background: Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) is a life-threatening invasive fungal infection in critically ill patients with COVID-19. However, only a few studies have reported CAPA in the Republic of Korea. Objective: To describe clinical characteristics of CAPA in patients at a tertiary care hospital in the Republic of Korea. Methods: This retrospective, observational consecutive case series study was conducted by reviewing the electronic medical records of patients who developed CAPA at Seoul National University Hospital from January 1, 2020, to August 31, 2021. CAPA was defined by European Confederation of Medical Mycology/International Society for Human and Animal Mycology (ECMM/ISHAM) consensus criteria. Patient demographics, comorbidities, corticosteroid use, clinical presentation, treatment, and outcomes were investigated. Results: Eleven patients were diagnosed with probable CAPA according to the ECMM/ISHAM criteria. One patient had classical host factor for invasive pulmonary aspergillosis before admission. All patients received corticosteroid therapy before CAPA diagnosis. The mean total corticosteroid administered before CAPA diagnosis was 220 mg of dexamethasone equivalent dose (range, 80~572 mg), and the mean duration of steroid therapy was 15 days (range, 4~34 days). The median time from intensive care unit admission to CAPA diagnosis was 12 days (range, 5~36 days). All individuals showed aggravation on chest X-rays. Ten patients were diagnosed with positive serum galactomannan (GM), and one was diagnosed with positive GM in a bronchoalveolar lavage specimen. Of the 11 patients, 8 received voriconazole-based antifungal therapy for a median of 30.5 days. Only two patients survived after antifungal treatment. Conclusion: These cases illustrate CAPA complicated in critically ill COVID-19 patients. The challenges in diagnosis and poor outcomes of CAPA emphasize the clinical suspicion and needs for further investigation.
참고문헌 (25)
- Koehler P, "Defining and managing COVID-19-associated pulmonary aspergillosis : the 2020 ECMM", ISHAM consensus criteria for research and clinical guidance, 2021, pp.21, e149~e162
- Verweij PE, "Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis", Intensive Care Med, 47, pp.819~834 (2021)
- 황영훈, "Coronavirus Disease 2019-Associated Pulmonary Aspergillosis", 대한의진균학회지, 27(1), pp.1~8 (2022), 대한의진균학회
- Donnelly JP, "Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium", Clin Infect Dis, 71, pp.1367~1376 (2020)
- Thompson GR, 3rd, "Aspergillus Infections", N Engl J Med, 385, pp.1496~1509 (2021)
- Zilberberg MD, "Burden of hospitalizations over time with invasive aspergillosis in the United States, 2004-2013", BMC Public Health, 19, pp.591~ (2019)
- Van de Veerdonk FL, "COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion", Lancet Respir Med, 9, pp.795~802 (2021)
- Mitaka H, "Incidence and mortality of COVID-19-associated pulmonary aspergillosis : A systematic review and meta-analysis", Mycoses, 64, pp.993~1001 (2021)
- Bartoletti M, "Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19 : a prospective study", Clin Infect Dis, 73, pp.e3606~e3614 (2021)
- Janssen NAF, "Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis", Emerg Infect Dis, 27, pp.2892~2898 (2021)
- White PL, "A national strategy to diagnose coronavirus disease 2019-associated invasive fungal disease in the intensive care unit", Clin Infect Dis, 73, pp.e1634~e1644 (2021)
- Dellière S, "Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients : a French multicentric retrospective cohort", Clin Microbiol Infect, 27, pp.790.e1~790.e5 (2020)
- Kim Si-Ho, "Risk Factors for Coronavirus Disease 2019 (COVID-19)-Associated Pulmonary Aspergillosis in Critically Ill Patients: A Nationwide, Multicenter, Retrospective Cohort Study", Journal of Korean Medical Science, 37(18), pp.1~12 (2022), 대한의학회[DOI]
- Raeseok Lee, "Risk factors and clinical impact of COVID-19- associated pulmonary aspergillosis: multicenter retrospective cohort study", The Korean Journal of Internal Medicine, 37(4), pp.851~863 (2022), 대한내과학회[DOI]
- Rouzé A, "COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection?", Curr Opin Crit Care, 28, pp.470~479 (2022)
- Hong W, "CT findings of COVID-19-associated pulmonary aspergillosis : a systematic review and individual patient data analysis", Clin Imaging, 90, pp.11~18 (2022)
- Agha RA, "The PROCESS 2020 guideline : updating consensus Preferred Reporting Of CasESeries in Surgery(PROCESS)guidelines", Int J Surg, 84, pp.231~235 (2020)
- RECOVERY Collaborative Group, "Dexamethasone in hospitalized patients with Covid-19", N Engl J Med, 384, pp.693~704 (2021)
- "Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19" (2022)[URL]
- Villar J, "Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial", Lancet Respir Med, 8, pp.267~276 (2020)
- Lormans P, "COVID-19 acquisition risk among ICU nursing staff with patient-driven use of aerosol-generating respiratory procedures and optimal use of personal protective equipment", Intensive Crit Care Nurs, 63, pp.102993~ (2021)
- Pritchett MA, "Society for advanced bronchoscopy consensus statement and guidelines for bronchoscopy and airway management amid the COVID-19pandemic", J Thorac Dis, 12, pp.1781~1798 (2020)
- Ergün M, "Aspergillus test profiles and mortality in critically ill COVID-19 patients", J Clin Microbiol, 59, pp.e0122921~ (2021)
- Prattes J, "Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients : results from a European confederation of medical mycology registry", Intensive Care Med, 47, pp.1158~1160 (2021)
- Maertens JA, "Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial", Lancet, 387, pp.760~769 (2016)